cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.20023160
title: Additional file 8 of Azacytidine arrests ripening in cultivated strawberry (Fragaria × ananassa) by repressing key genes and altering hormone contents

description: Additional file 8.
DOI: 10.6084/m9.figshare.20023160.v1
title: Additional file 8 of Azacytidine arrests ripening in cultivated strawberry (Fragaria × ananassa) by repressing key genes and altering hormone contents

description: Additional file 8.
DOI: 10.6084/m9.figshare.20023165
title: Additional file 2 of OptNCMiner: a deep learning approach for the discovery of natural compounds modulating disease-specific multi-targets

description: Additional file 2: Excel sheet of in silico docking results of false positives.
DOI: 10.6084/m9.figshare.20023168.v1
title: Additional file 3 of OptNCMiner: a deep learning approach for the discovery of natural compounds modulating disease-specific multi-targets

description: Additional file 3: Excel sheet of predicted interactions between target proteins and NCs and NC containing natural sources.
DOI: 10.6084/m9.figshare.20023165.v1
title: Additional file 2 of OptNCMiner: a deep learning approach for the discovery of natural compounds modulating disease-specific multi-targets

description: Additional file 2: Excel sheet of in silico docking results of false positives.
DOI: 10.6084/m9.figshare.20023168
title: Additional file 3 of OptNCMiner: a deep learning approach for the discovery of natural compounds modulating disease-specific multi-targets

description: Additional file 3: Excel sheet of predicted interactions between target proteins and NCs and NC containing natural sources.
DOI: 10.6084/m9.figshare.20023046.v1
title: BNF dataset for carbon hypothesis.xls

description: This meta-dataset includes data of N fixation rates and diazotroph (N-fixing microorganism) community structure in response to C and N addition across multiple terrestrial ecosystems, which are compiled from 127 literature sources published between April 1970 and December 2021.
DOI: 10.34740/kaggle/dsv/3762960
title: BBC News
DOI: 10.3886/e100510v2-120220
title: MacArthur Mental Health Court Study

description: The MacArthur Mental Health Court (MHC) project is a longitudinal study examining the effectiveness of these specialty courts in reducing recidivism, reducing the number of jail days and stays, and increasing access to community mental health and substance use treatment. The study included four data collection sites (two in CA, one in MN, and one in IN), two samples (newly enrolled MHC clients and a comparison sample of offenders with mental illness in the traditional criminal justice system), two interview time points (baseline and 6-month follow-up), and the collection of objective criminal justice and court data up to 18 months post-enrollment in the MHC/post-arrest. This comprehensive project was funded by the John D. and Catherine T. MacArthur Network on Community Mandated Treatment, led by Professor John Monahan, and was conducted by Policy Research Associates (Principal Investigator: Dr. Henry J. Steadman).
description: Presence of Common Scales: Several Likert scales were used.<br>Colorado Symptoms Inventory<br>Insight and Treatment Attitudes Questionnaire
description: There were two samples: MHC and TAU (treatment as usual) samples.<br>The MHC sample were newly enrolled clients in the four participating courts who provided informed consent to participate.<br>The TAU sample were newly arrested offenders with mental health problems in the jails of the same four cities as the courts, who also provided informed consent. In addition, the TAU sample had to be eligible for the MHC (criteria relating to criminal charges and mental health) but could not have been referred to, or rejected from the MHC. <br><br><br>
description: Newly enrolled mental health court (MHC) participants in four locations<br>Newly arrested offenders with mental health issues in four locations<br><br><br>.
description: face-to-face interview; Survey data at baseline (entry into MHC or criminal justice system)<br>Survey data at 6-month follow-up<br>Administrative data from courts
DOI: 10.5281/zenodo.6622183
title: Supplementary Tables for the article"One-to-one Coupling between Southern Ocean Productivity and Antarctica Climate"

description: Supplementary Tables for the article"One-to-one Coupling between Southern Ocean Productivity and Antarctica Climate". Table S1. Tie points in the age model of Site U1537; Table S2. Age-depth model and uncertainties at Site U1537; Table S3. Natural gamma radiation data at Site U1537; Table S4. Color reflectance component b* data at Site U1537; Table S5. Ca counts data at Site U1537; Table S6. Magnetic susceptibility data at Site U1537.
DOI: 10.5281/zenodo.6622182
title: Supplementary Tables for the article"One-to-one Coupling between Southern Ocean Productivity and Antarctica Climate"

description: Supplementary Tables for the article"One-to-one Coupling between Southern Ocean Productivity and Antarctica Climate". Table S1. Tie points in the age model of Site U1537; Table S2. Age-depth model and uncertainties at Site U1537; Table S3. Natural gamma radiation data at Site U1537; Table S4. Color reflectance component b* data at Site U1537; Table S5. Ca counts data at Site U1537; Table S6. Magnetic susceptibility data at Site U1537.
DOI: 10.25934/pr00003792.0
title: Available IPD datapackage for study 'Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis'

description: This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in adolescent and adult subjects with atopic dermatitis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and application frequency in future clinical studies. This is a multicenter (United States, Canada, and Japan), randomized, double-blind (sponsor-unblind), vehicle-controlled, 6-arm, parallel-group, dose-finding study in adolescent and adult subjects with atopic dermatitis. Two concentrations of GSK2894512 cream (0.5% and 1%) and a vehicle control cream will be equally randomized and evaluated following application to all atopic dermatitis lesions (except on the scalp) once daily (evening) or twice daily (morning and evening) for 12 weeks. This study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of subject participation will be approximately 16 to 20 weeks. Approximately 270 adolescent and adult males and females subjects with atopic dermatitis will be screened in order to have at least 228 randomized subjects (38 subjects for each of the 6 treatment groups) and approximately 204 evaluable subjects overall. Approximately 30 subjects will be randomized in Japan to achieve at least 24 evaluable Japanese subjects.
DOI: 10.25934/pr00007243
title: Developing Models from Existing Atopic Dermatitis Outcome Data 

description: Background
Atopic dermatitis (atopic eczema) is an inflammatory skin disease affecting children and adults.  Usually, the disease presents in childhood with red itchy skin lesions.  Later in life these same children often develop asthma and/or allergic rhinitis. Atopic dermatitis can also present in adulthood or persist from childhood to adulthood in some cases. Currently, around 16.5 million adults have atopic dermatitis, with the disease incidence reportedly being on the rise.  Patients with atopic dermatitis also suffer from other comorbidities including skin infections, anxiety and depression.  

Necessity of the research
In order for new drugs to be developed or the efficacy of one treatment to be compared to another, investigators need accurate tools to assess disease severity. This will allow them to determine how much the patient improves and how fast they improve after starting the treatment. 

How the research will add to medical science or patient care
The ultimate goal of the type of research proposed herein is to develop improved tools or to simplify existing tools to assess skin disease severity. Such tools can then be used in the development of new treatments for skin disease. 

How the research will be conducted/What design and methods you have you chosen and why
The proposed research will study the relationships between the individual components of the various efficacy assessment tools used to determine skin disease severity. To accomplish this we will employ various statistical methodologies. 

We hope to conduct this analysis using data from both atopic dermatitis and psoriasis clinical trial datasets but other well-curated clinical trial datasets are also of interest, including trials outside the field of dermatology.
DOI: 10.6084/m9.figshare.20023673
title: Xu et al 2022 GRL-Table SI.xlsx

description: <strong>Supporting Information</strong> Table S1-S5 for Closing the global marine 226Ra budget reveals the biological pump as a dominant removal flux in the upper ocean <br> <strong>Table S1</strong>. River water and 226Ra fluxes, dissolved 226Ra concentration, and sediment desorption efficiency for rivers around the world. <strong>Table S2</strong>. Diffusive flux of 226Ra from coastal and shelf sediment. <strong>Table S3</strong>: Summary of 226Ra activity for all oceans. <strong>Table S4</strong>: Upwelling-downwelling velocity between the upper and lower ocean. <strong>Table S5</strong>. Estimates and values of the particle scavenging rate coefficient (<em>k</em>) in the ocean.
DOI: 10.6084/m9.figshare.20023832
title: Data sheet.xlsx

description: Data Sheet. Musical Therapy.
DOI: 10.5281/zenodo.6622317
title: ROADMAP bed files binning by bedtools

description: Roadmap ChIP-Seq data
description: Center for Information Biology W412 National Institute of Genetics 1111, Yata
DOI: 10.5281/zenodo.6622331
title: ROADMAP bed files binning by bedtools

description: Roadmap ChIP-Seq data
description: Center for Information Biology W412 National Institute of Genetics 1111, Yata
DOI: 10.5281/zenodo.6622316
title: ROADMAP bed files binning by bedtools

description: Roadmap ChIP-Seq data
description: Center for Information Biology W412 National Institute of Genetics 1111, Yata
DOI: 10.17608/k6.auckland.20024195
title: World list of isopod species and their authorities_updated_2021.xlsx

description: This dataset contains a list of the world's isopod species obtained from the World Register of Marine Species (WoRMS), as well as a list of first authors from the species' descriptions. Additional information on the environment, authorities and year of description is provided. Temporal range from 1758 to 2021
DOI: 10.6084/m9.figshare.20024282
title: Supplementary Material for: Factors Associated with Severity of Acute Kidney Injury and Adverse Outcomes in Critically Ill Patients with COVID-19

description: <b><i>Background:</i></b> Acute kidney injury (AKI) is a well-recognized complication of coronavirus disease 2019 (COVID-19). The short and long-term outcomes of patients who develop AKI have not been well characterized. <b><i>Methods:</i></b> In this multicenter retrospective cohort study, we describe the clinical characteristics and outcomes of critically ill adults with severe COVID-19 and AKI. Patient-level variables were extracted from the electronic medical record. Using nadir-to-peak serum creatinine, AKI was defined using the KDIGO definition. Multivariable logistic regression analyses examined factors associated with development of moderate-to-severe (stage 2–3) AKI, severe (stage-3) AKI, and the composite of renal replacement therapy (RRT) or in-hospital death. <b><i>Results:</i></b> Among 459 critically ill adults with COVID-19, 371 (80.1%) developed AKI, with 179 (37.9%) developing stage-3 AKI. Male gender, black and Asian/Native American race, lower baseline estimated glomerular filtration rate (eGFR), higher body mass index (BMI), and higher Acute Physiology and Chronic Health Evaluation (APACHE) IV score were more prevalent among patients with severe AKI, as were systemic markers of inflammation. On multivariable analysis, male gender, black and Asian/Native American race, higher APACHE IV score, lower baseline eGFR, and higher BMI (mainly the highest BMI stratum ≥35 kg/m<sup>2</sup>) were independently associated with higher stages of AKI severity. Male gender, lower baseline eGFR, and higher APACHE IV score were also independently associated with the composite of RRT or in-hospital death. Moderate-to-severe AKI and severe AKI were independently associated with in-hospital death, and there was a significant interaction between BMI and moderate-to-severe AKI for the outcome of in-hospital death. Among 83 (18.1%) patients who required RRT, 27 (32.5%) survived, and 12 (44.4%) remained dialysis-dependent at discharge. At 3 and 6 months, 5 (41.7%) and 4 (33.3%) remained dialysis-dependent, respectively. <b><i>Conclusions:</i></b> AKI is common in critically ill adults with COVID-19. Several patient-level risk factors are associated with higher stages of AKI severity. BMI might be an effect modifier of AKI severity for in-hospital death. Among AKI survivors, there is a high rate of short- and long-term dialysis dependence.
DOI: 10.6084/m9.figshare.20024282.v1
title: Supplementary Material for: Factors Associated with Severity of Acute Kidney Injury and Adverse Outcomes in Critically Ill Patients with COVID-19

description: <b><i>Background:</i></b> Acute kidney injury (AKI) is a well-recognized complication of coronavirus disease 2019 (COVID-19). The short and long-term outcomes of patients who develop AKI have not been well characterized. <b><i>Methods:</i></b> In this multicenter retrospective cohort study, we describe the clinical characteristics and outcomes of critically ill adults with severe COVID-19 and AKI. Patient-level variables were extracted from the electronic medical record. Using nadir-to-peak serum creatinine, AKI was defined using the KDIGO definition. Multivariable logistic regression analyses examined factors associated with development of moderate-to-severe (stage 2–3) AKI, severe (stage-3) AKI, and the composite of renal replacement therapy (RRT) or in-hospital death. <b><i>Results:</i></b> Among 459 critically ill adults with COVID-19, 371 (80.1%) developed AKI, with 179 (37.9%) developing stage-3 AKI. Male gender, black and Asian/Native American race, lower baseline estimated glomerular filtration rate (eGFR), higher body mass index (BMI), and higher Acute Physiology and Chronic Health Evaluation (APACHE) IV score were more prevalent among patients with severe AKI, as were systemic markers of inflammation. On multivariable analysis, male gender, black and Asian/Native American race, higher APACHE IV score, lower baseline eGFR, and higher BMI (mainly the highest BMI stratum ≥35 kg/m<sup>2</sup>) were independently associated with higher stages of AKI severity. Male gender, lower baseline eGFR, and higher APACHE IV score were also independently associated with the composite of RRT or in-hospital death. Moderate-to-severe AKI and severe AKI were independently associated with in-hospital death, and there was a significant interaction between BMI and moderate-to-severe AKI for the outcome of in-hospital death. Among 83 (18.1%) patients who required RRT, 27 (32.5%) survived, and 12 (44.4%) remained dialysis-dependent at discharge. At 3 and 6 months, 5 (41.7%) and 4 (33.3%) remained dialysis-dependent, respectively. <b><i>Conclusions:</i></b> AKI is common in critically ill adults with COVID-19. Several patient-level risk factors are associated with higher stages of AKI severity. BMI might be an effect modifier of AKI severity for in-hospital death. Among AKI survivors, there is a high rate of short- and long-term dialysis dependence.
DOI: 10.5281/zenodo.6622424
title: Sample FastQ file for sm-SNIPER workflow

description: Reference data for sm-SNIPER workflow.
DOI: 10.5281/zenodo.6622392
title: Compound hot and dry and wet and windy events in CMIP6 models

description: NetCDF files containing maps of return periods (in years) for the joint occurrence of strong surface winds (sfcWind) and heavy rain (pr) and heatwaves (EHF) and drought (SPI) as realised by models participating in the Coupled Model Intercomparison Project Round 6 (CMIP6). Included is output from models that provided daily data for sfcWind, pr, tmax and tmin (to calculate EHF) and experiments historical, SSP126, SSP245, and SSP585 for ensemble member r1i1p1f1. The base period for the determination of hazard thresholds was 1980 – 2014 for all experiments. Time periods over which return periods were calculated were 1980 – 2014 for the 'historical' experiment and 2066 – 2100 for experiments 'SSP126', 'SSP245', and 'SSP585'. Values for return periods are determined following the method in Ridder et al. (2020a) doi: 10.1038/s41467-020-19639-3; Ridder et al. (2020b) doi: 10.1029/2020GL091152 and Ridder et al. (2021) doi: 10.1038/s41612-021-00224-4. Name convention: historical experiments: <br> <em>map_RP_${hazardX}_${hazardY}_${CMIP6model}_historical_r1i1p1f1_${model_grid}_19800101_20141231.nc</em> ScenarioMIPs:<br> map_RP_<em>${hazardX}_${hazardY}_${CMIP6model}</em>_historic_threshold_${experiment}_r1i1p1f1_2066-2100.nc
description: {"references": ["Ridder, Nina et al. (2020). ''Global Hotspots Global hotspots for the occurrence of compound events\", Nat. Comms.", "Ridder, Nina et al. (2021). \"Do CMIP6 climate models simulate global or regional compound events skillfully?\", GRL.", "Ridder, Nina et al. (2022). \"Increased occurrence of high impact compound events under climate change\", npj Climate and Atmospheric Science"]}
DOI: 10.5281/zenodo.6622391
title: Compound hot and dry and wet and windy events in CMIP6 models

description: NetCDF files containing maps of return periods (in years) for the joint occurrence of strong surface winds (sfcWind) and heavy rain (pr) and heatwaves (EHF) and drought (SPI) as realised by models participating in the Coupled Model Intercomparison Project Round 6 (CMIP6). Included is output from models that provided daily data for sfcWind, pr, tmax and tmin (to calculate EHF) and experiments historical, SSP126, SSP245, and SSP585 for ensemble member r1i1p1f1. The base period for the determination of hazard thresholds was 1980 – 2014 for all experiments. Time periods over which return periods were calculated were 1980 – 2014 for the 'historical' experiment and 2066 – 2100 for experiments 'SSP126', 'SSP245', and 'SSP585'. Values for return periods are determined following the method in Ridder et al. (2020a) doi: 10.1038/s41467-020-19639-3; Ridder et al. (2020b) doi: 10.1029/2020GL091152 and Ridder et al. (2021) doi: 10.1038/s41612-021-00224-4. Name convention: historical experiments: <br> <em>map_RP_${hazardX}_${hazardY}_${CMIP6model}_historical_r1i1p1f1_${model_grid}_19800101_20141231.nc</em> ScenarioMIPs:<br> map_RP_<em>${hazardX}_${hazardY}_${CMIP6model}</em>_historic_threshold_${experiment}_r1i1p1f1_2066-2100.nc
description: {"references": ["Ridder, Nina et al. (2020). ''Global Hotspots Global hotspots for the occurrence of compound events\", Nat. Comms.", "Ridder, Nina et al. (2021). \"Do CMIP6 climate models simulate global or regional compound events skillfully?\", GRL.", "Ridder, Nina et al. (2022). \"Increased occurrence of high impact compound events under climate change\", npj Climate and Atmospheric Science"]}
DOI: 10.6084/m9.figshare.20024279
title: S-wave velocity in Central Japan Island estimated by adjoint tomography

description: S-wave velocity model (5, 10, 25, 35km depths) in Central Japan Island estimated by adjoint tomography
DOI: 10.6084/m9.figshare.20024279.v1
title: S-wave velocity in Central Japan Island estimated by adjoint tomography

description: S-wave velocity model (5, 10, 25, 35km depths) in Central Japan Island estimated by adjoint tomography
DOI: 10.6084/m9.figshare.19754395
title: Supplementary Material for: Effect of Germline MEFV polymorphisms on the prognosis of Japanese children with cancer: A regional analysis

description: Introduction: MEFV is the gene responsible for familial Mediterranean fever (FMF). It encodes pyrin, which controls inflammation; Besides, previous studies have reported that some germline MEFV variants were associated with tumour susceptibility. Materials and Methods: The loci of 12 germline MEFV variants were genotyped in 153 Japanese children with cancer, and the frequencies of these variants among the patient groups were compared with those in the general Japanese population. Additionally, the relationship between these variants and clinical data, including relapse and death, was investigated. Results: Minor allele frequencies did not differ between patients and the general population, or between sex, age at diagnosis, and diagnosis among patients. P369S/R408Q associated with significantly lower relapse-free survival in all patient analyses and in patients with solid tumours. Additionally, although the results were not significant, E148Q/L110P was likely to associate with worse relapse-free survival in patients with solid tumours. Discussion/Conclusion: Despite several limitations, this study provided the novel insight that the germline MEFV variants are associated with the clinical outcome of paediatric cancer.
DOI: 10.6084/m9.figshare.19754395.v1
title: Supplementary Material for: Effect of Germline MEFV polymorphisms on the prognosis of Japanese children with cancer: A regional analysis

description: Introduction: MEFV is the gene responsible for familial Mediterranean fever (FMF). It encodes pyrin, which controls inflammation; Besides, previous studies have reported that some germline MEFV variants were associated with tumour susceptibility. Materials and Methods: The loci of 12 germline MEFV variants were genotyped in 153 Japanese children with cancer, and the frequencies of these variants among the patient groups were compared with those in the general Japanese population. Additionally, the relationship between these variants and clinical data, including relapse and death, was investigated. Results: Minor allele frequencies did not differ between patients and the general population, or between sex, age at diagnosis, and diagnosis among patients. P369S/R408Q associated with significantly lower relapse-free survival in all patient analyses and in patients with solid tumours. Additionally, although the results were not significant, E148Q/L110P was likely to associate with worse relapse-free survival in patients with solid tumours. Discussion/Conclusion: Despite several limitations, this study provided the novel insight that the germline MEFV variants are associated with the clinical outcome of paediatric cancer.